<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830267</url>
  </required_header>
  <id_info>
    <org_study_id>Camresbrt</org_study_id>
    <nct_id>NCT04830267</nct_id>
  </id_info>
  <brief_title>The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M HNSCC</brief_title>
  <official_title>A Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing University Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand&#xD;
      programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this&#xD;
      by allowing immune cells to fight the cancer. Camrelizumab has been approved by China's&#xD;
      National Medical Products Administration (NMPA) for the treatment of esophageal cancer, liver&#xD;
      cancer and lung cancer. It is currently under study for the treatment of head and neck&#xD;
      squamous cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will be equally randomized between the 2 following treatment groups:&#xD;
&#xD;
      Standard treatment group: Camrelizumab 200mg IV every 2 weeks. Experimental group:&#xD;
      Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Time Frame: 96 weeks</time_frame>
    <description>As determined by the investigator using RECIST 1.1 criteria between patients receiving Camrelizumab and stereotactic body radiotherapy and those receiving Camrelizumab alone. BOR rate is defined as the number of patients randomized to a given arm with a best overall response of complete response (CR) or partial response (PR) of non-irradiated lesions divided by the total number of patients randomized to the given arm. In order to ascertain this endpoint, efforts will be made so that patients will be followed for 96 weeks or until progression of disease (and treatment cessation), whichever comes first. At each time-point, subjects should have CT/MR of neck, chest, abdomen, and pelvis with contrast.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Camrelizumab 200mg IV every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic body radiotherapy plus Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.</description>
    <arm_group_label>Camrelizumab alone</arm_group_label>
    <arm_group_label>Stereotactic body radiotherapy plus Camrelizumab</arm_group_label>
    <other_name>Anti-PD-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy</intervention_name>
    <description>Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).</description>
    <arm_group_label>Stereotactic body radiotherapy plus Camrelizumab</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent&#xD;
&#xD;
          2. Subjects must have signed and dated an IRB/IEC approved written informed consent form&#xD;
             in accordance with regulatory and institutional guidelines.&#xD;
&#xD;
          3. Subjects must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             laboratory testing, and other study obligations.&#xD;
&#xD;
          4. Target Population:&#xD;
&#xD;
             Males and females ≥ 18 years of age Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status ≤ 2. Histologically confirmed metastatic or recurrent HNSCC,&#xD;
             including nasopharynx WHO Type I-III histologies.&#xD;
&#xD;
          5. Subjects must have at least two lesions:&#xD;
&#xD;
             At least one lesion must be safely amenable to irradiation. This can be a lesion that&#xD;
             was previously irradiated as long as prior radiation was at least 6 months prior to&#xD;
             projected first fraction of SBRT and as long as reirradiation dose constraints are&#xD;
             being met.&#xD;
&#xD;
             A separate, not-to-be-irradiated lesion measurable by CT or MRI per RECIST 1.1&#xD;
             criteria.&#xD;
&#xD;
          6. A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 5&#xD;
             unstained slides of tumor sample obtained via excisional, incisional, or core needle&#xD;
             biopsy from a metastatic or loco-regionally recurrent lesion. If 3 unstained are&#xD;
             unavailable from a metastatic or loco-regionally recurrent lesion, with permission of&#xD;
             the PI, FFPE tumor tissue from the primary disease site at the time of original&#xD;
             diagnosis is acceptable.&#xD;
&#xD;
          7. For oropharynx or nasopharynx primary lesions, documentation of viral status is&#xD;
             required (e.g. high risk HPV sub-type PCR, p16 IHC, HPV ISH, EBER, etc). Tests done on&#xD;
             primary tumor specimens from date of initial diagnosis at outside institutions are&#xD;
             sufficient to meet this criterion&#xD;
&#xD;
          8. Prior palliative or curative radiotherapy must be completed at least 14 days prior to&#xD;
             randomization.&#xD;
&#xD;
          9. Immunosuppressive doses of systemic medication, such as steroids or absorbed topical&#xD;
             steroids (doses &gt;10mg/day prednisone or equivalent) must be discontinued at least 14&#xD;
             days prior to Camrelizumab administration.&#xD;
&#xD;
         10. Screening laboratory values must meet the following criteria (using CTCAE v4.0) and&#xD;
             should be obtained within 28 days prior to randomization:&#xD;
&#xD;
             WBC ≥ 2 K/microliter Neutrophils ≥ 1.5 K/microliter Platelets ≥ 100 K/microliter&#xD;
             Hemoglobin ≥ 9.0 g/deciliter Serum Creatinine ≤ 1.5 x ULN or creatinine clearance &gt;&#xD;
             40ml/min using the Cockcroft-Gault formula.&#xD;
&#xD;
             Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in&#xD;
             mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in&#xD;
             mg/dL AST/ALT ≤ 3 x ULN Total bilirubin &lt;1.5 x ULN (except subjects with Gilbert&#xD;
             Syndrome who can have total bilirubin &lt;3.0 mg/deciliter).&#xD;
&#xD;
             Subjects must have a resting baseline O2 saturation by pulse oximetry of &gt;=92% at&#xD;
             rest.&#xD;
&#xD;
         11. Reproductive Status:&#xD;
&#xD;
        Women of childbearing potential must have a negative serum or urine pregnancy test (minimum&#xD;
        sensitivity 25 IU/L or equivalent units of HCG) within 28 days prior to randomization.&#xD;
&#xD;
        Women must not be breastfeeding Women of childbearing potential must agree to follow&#xD;
        instructions for method(s) of contraception from time of enrollment for the duration of&#xD;
        treatment with Camrelizumab plus 5 half- lives plus 30 days for a total of 23 weeks post&#xD;
        treatment completion.&#xD;
&#xD;
        Men who are sexually active with WOCBP must use any contraceptive method with a failure&#xD;
        rate of less than 1% per year. Men receiving Camrelizumab and who are sexually active with&#xD;
        WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last&#xD;
        dose of investigational product.&#xD;
&#xD;
        Women who are not of childbearing potential (i.e., who are postmenopausal or surgically&#xD;
        sterile as well as azoospermic men do not require contraception.&#xD;
&#xD;
        Azoospermic males and women of childbearing potential who are continuously not&#xD;
        heterosexually active are exempt from contraceptive requirements. However, they still must&#xD;
        have a pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target Disease Exceptions:&#xD;
&#xD;
             Active brain metastases (untreated brain metastases or growth on imaging as defined&#xD;
             below) or leptomeningeal disease are not allowed. Subjects with brain metastases are&#xD;
             eligible if these have been treated and there is no MRI (or CT if MRI contraindicated)&#xD;
             evidence of progression for at least 8 weeks after treatment for these metastases is&#xD;
             complete and within 28 days prior to first study treatment.&#xD;
&#xD;
             Histologically confirmed non-squamous histologies are not allowed; an exception is&#xD;
             made for WHO Type I-III nasopharynx histologies.&#xD;
&#xD;
          2. Medical History and Concurrent Diseases:&#xD;
&#xD;
             Any medical disorder that, in the opinion of the investigator, might increase the risk&#xD;
             associated with study participation or interferes with the interpretation of study&#xD;
             results.&#xD;
&#xD;
             Prior active malignancy within the previous 3 years except for locally curable cancers&#xD;
             such as basal or squamous skin cancer, superficial bladder, low risk prostate cancer,&#xD;
             breast, or cervix cancer. If other prior malignancy was active within prior 3 years,&#xD;
             enrollment requires approval of a principal investigator.&#xD;
&#xD;
             Patients should be excluded if they have an active, known or suspected autoimmune&#xD;
             disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes&#xD;
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger Subjects with a condition requiring&#xD;
             systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone equivalents)&#xD;
             or other immunosuppressive medications within 14 days of study drug administration&#xD;
             should be excluded. Inhaled or topical steroids and adrenal replacement doses &gt;10mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          3. Physical and Laboratory Test Findings:&#xD;
&#xD;
             Positive test for hepatitis B virus surface antigen or hepatitis C virus ribonucleic&#xD;
             acid indicating acute or chronic infection.&#xD;
&#xD;
             Known history of testing positive for HIV or known AIDS. Any grade 4 laboratory&#xD;
             abnormalities. Allergies and Adverse Drug Reaction History of allergy to Camrelizumab&#xD;
             components History of severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          4. Prohibited or Restricted Treatments:&#xD;
&#xD;
        The following medications are prohibited during the study:&#xD;
&#xD;
        Immunosuppressive agents (except to treat a drug-related adverse event). Systemic&#xD;
        corticosteroids &gt; 10 mg daily prednisone equivalent save for exclusion outlined in the&#xD;
        below paragraphs.&#xD;
&#xD;
        Any concurrent chemotherapy, hormonal therapy, immunotherapy, or investigational agents for&#xD;
        treatment of cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Wang, Ph.D, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiangdong Sui, Ph.D, M.D.</last_name>
    <phone>13594190011</phone>
    <email>jiangdong.sui@cqu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Wang, Ph.D, M.D.</last_name>
    <phone>13996412826</phone>
    <email>yingwang197011@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangdong Sui, Ph.D, M. D.</last_name>
      <phone>13594910011</phone>
      <email>jiangdong.sui@cqu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ying Wang, Ph.D, M. D.</last_name>
      <phone>13996412826</phone>
      <email>yingwang197011@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Wang, Ph.D, M. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiangdong Sui, Ph.D, M. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.</citation>
    <PMID>30191365</PMID>
  </reference>
  <reference>
    <citation>Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. Erratum in: J Clin Oncol. 2019 Feb 10;37(5):443.</citation>
    <PMID>30110194</PMID>
  </reference>
  <reference>
    <citation>Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.</citation>
    <PMID>30213452</PMID>
  </reference>
  <reference>
    <citation>Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011 Apr 1;71(7):2488-96. doi: 10.1158/0008-5472.CAN-10-2820. Epub 2011 Feb 7.</citation>
    <PMID>21300764</PMID>
  </reference>
  <reference>
    <citation>Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, van den Broek M. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res. 2013 Sep 1;19(17):4843-53. doi: 10.1158/1078-0432.CCR-13-0352. Epub 2013 Jul 16.</citation>
    <PMID>23861514</PMID>
  </reference>
  <reference>
    <citation>Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687-95. doi: 10.1172/JCI67313. Epub 2014 Jan 2.</citation>
    <PMID>24382348</PMID>
  </reference>
  <reference>
    <citation>Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.</citation>
    <PMID>22397654</PMID>
  </reference>
  <reference>
    <citation>Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013 Dec;1(6):365-72. doi: 10.1158/2326-6066.CIR-13-0115.</citation>
    <PMID>24563870</PMID>
  </reference>
  <reference>
    <citation>Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014 Jul;50(7):627-32. doi: 10.1016/j.oraloncology.2014.04.003. Epub 2014 May 10. Review.</citation>
    <PMID>24819861</PMID>
  </reference>
  <reference>
    <citation>McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, Lefkowitz R, Spielsinger D, Zhang Z, Flynn J, Dunn L, Ho A, Riaz N, Pfister D, Lee N. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2021 Jan 1;39(1):30-37. doi: 10.1200/JCO.20.00290. Epub 2020 Aug 21.</citation>
    <PMID>32822275</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing University Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Ying Wang</investigator_full_name>
    <investigator_title>Associate Director of Chongqing University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>Camrelizumab</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>R/M head and neck squamous cell carcinoma</keyword>
  <keyword>Best overall response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

